DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.12
+0.03 (+2.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.09
Open1.10
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.10 - 1.13
52 Week Range0.74 - 2.17
Volume216,794
Avg. Volume626,601
Market Cap166.372M
Beta2.62
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateMar 12, 2018 - Mar 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.97
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)

    CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time. The call will feature a presentation by KOL Keith Lindor, MD, who will present an overview of primary sclerosing cholangitis, including an overview of the disease and its progression, current treatment options and the treatment landscape for PSC.  He will be available to answer questions at the conclusion of the call. Dr. Keith Lindor is Senior Advisor to the Provost at Arizona State University (ASU) and a Professor of Medicine at Mayo Clinic.

  • PR Newswire8 days ago

    DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics

    CUPERTINO, Calif. , Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New ...

  • PR Newswire2 months ago

    DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot

    CUPERTINO, Calif. , Dec. 13, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has accepted ...

  • ACCESSWIRE2 months ago

    DURECT Corporation: New Patent Revenue, Analysts Review, Earnings and Current Pipeline Progress

    NEW YORK, NY / ACCESSWIRE / December 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Capital Cube2 months ago

    ETFs with exposure to DURECT Corp. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to DURECT Corp. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube3 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Zogenix, Inc., Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Heron Therapeutics Inc and Pacira Pharmaceuticals, Inc. (PTIE-US, ZGNX-US, JNJ-US, PFE-US, LLY-US, ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to DURECT Corp. : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT

    Q3 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research4 months ago

    DRRX: Focus will be Shifted to DUR-928 Programs

    Revenue from R&D collaborations was $5.6 million in third quarter 2017, compared to $0.4 million in third quarter 2016. A large portion of that increase related to the recognition of deferred revenue from upfront fees already received by the company.

  • Associated Press4 months ago

    Durect tops Street 3Q forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 4 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • PR Newswire4 months ago

    DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call

    CUPERTINO, Calif. , Oct. 26, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call ...

  • PR Newswire4 months ago

    DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint

    CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.  While results trended in favor of POSIMIR versus the comparator, they did not achieve statistical significance.  POSIMIR is an investigational drug candidate being developed for the treatment of post-surgical pain.

  • Capital Cube4 months ago

    ETFs with exposure to DURECT Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Marketwired5 months ago

    Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia

    A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. In an Oct. 2 press release, ...

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube5 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 4.32 million, Net Earnings of USD -9.93 million. Gross margins widened from 71.08% to 78.61% compared to the same period last year, operating (EBITDA) margins now -214.24% from -265.79%. Change in operating cash ... Read more (Read more...)

  • Zacks Small Cap Research5 months ago

    DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC

    Pursuant to the agreement, DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).

  • PR Newswire5 months ago

    DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement

    CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (INDV.L), whereby DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior today announced that it has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).

  • PR Newswire5 months ago

    DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development

    CUPERTINO, Calif. , Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. Theeuwes ...

  • PR Newswire6 months ago

    DURECT to Participate in Upcoming Healthcare Conferences

    James E. Brown, President and CEO, will present at the Rodman & Renshaw Global Investment Conference on Tuesday, September 12 at 12:30 p.m. Eastern time. The conference is being held at the Lotte New York Palace Hotel in New York City.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research6 months ago

    DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States

    On May 8, 2017, Durect (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States. The $43 million could be received when Durect resubmits the NDA and get approval for Posimir which could be done in 1Q18.